Compare Regeneron Pharmaceuticals Inc (REGN) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vital Farms Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Vital Farms Inc trades at $13.03 (market cap $561.74M). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 126× Vital Farms Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| REGN | VITL | |
|---|---|---|
Market Cap | $70.79B | $561.74M |
Sector | Health | Consumer Staples |
52-Week High | $812.27 | $52.41 |
52-Week Low | $545.46 | $8.28 |
Enterprise Value | $64.74B | $564.55M |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Vital Farms (VITL) trades at $13.76, up 1.55% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 15.44% ROE and trades at a modest P/E of 13.25. Recent earnings have been mixed, with a Q3 2025 beat but Q1 2026 miss, while analyst sentiment remains positive with 56% buy ratings. Net cash flow is negative due to significant investing activities, and a class action lawsuit filed in May 2026 adds legal overhang.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but near-term performance hinges on reversing negative earnings surprises and managing legal risks. The consensus price target of $13.50 suggests limited upside from current levels, with execution on revenue growth and margin stabilization key to driving shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
